TrialESMO open2026

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus.

J B Aragon-Ching et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.